Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
JAMA Oncol
; 8(7): 1001-1009, 2022 07 01.
Article
en En
| MEDLINE
| ID: mdl-35551299
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Neoplasias Endometriales
Tipo de estudio:
Clinical_trials
/
Etiology_studies
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article